Prostate cancer probability after total PSA and percent free PSA determination

• Published in: The International journal of biological markers Vol. 13; no. 2; p. 77
• Main Authors: Mione, R, Barioli, P, Barichello, M, Zattoni, F, Prayer-Galetti, T, Plebani, M, Aimo, G, Terrone, C, Manferrari, F, Madeddu, G, Caberlotto, L, Fandella, A, Pianon, C, Vianello, L, Gion, M
• Format: Journal Article
• Language: English
• Published: United States 01-04-1998
• Subjects: Aged; Diagnosis, Differential; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen - analysis; Prostatic Hyperplasia - diagnosis; Prostatic Neoplasms - diagnosis; Sensitivity and Specificity
• ISSN: 0393-6155
• DOI: 10.1177/172460089801300203

The percent free PSA value is a promising diagnostic tool for prostate cancer. However, its actual role has not yet been established because of the widely diverging sensitivity and specificity values. This could depend at least in part on analytical difficulties, since the free PSA concentration is much lower than that of total PSA. The present investigation was designed to evaluate the diagnostic performance of the percent free PSA in the most favorable analytical conditions.
81 patients affected by newly diagnosed, untreated primary prostate cancer (CaP) and 239 patients with untreated benign prostatic hyperplasia (BPH) were prospectively enrolled. Hybritech total and free PSA were measured by the same technician using the same reagent batch.
The percent free PSA was not significantly associated with age, tumor stage, gland volume, Gleason score, and total PSA, nor was it significantly affected by concomitant prostatic complications either in CaP or BPH. Percent free PSA was more effective than total PSA in the differential diagnosis between CaP and BPH in every evaluated dose range of total PSA. Percent free PSA determination could have reduced the rate of unnecessary biopsies in cases with total PSA > or = 4 ng/mL and > or = 10 ng/mL (avoided biopsies 61% and 63%, respectively). The post-test probability of the disease, which represents the proportion of patients with a positive percent free PSA value who have the disease, was, however, relatively low in younger patients with total PSA within the normal range.
The diagnostic performance of the percent free PSA value is enhanced when the methodological variability is reduced, particularly in men with low total PSA. Percent free PSA is superior to total PSA in distinguishing primary CaP from BPH in patients with total PSA between 2 and 30 ng/mL. The percent free PSA value is effective in reducing the rate of unnecessary biopsies in men with total PSA higher than 4 or 10 ng/mL. However, due to its relatively low post-test probability, the percent free PSA value should be interpreted with caution in the decision-making related to individual patients and should be used in association with clinical and instrumental evaluation of the patient.